Latest Content

Recent research data assessed the potential use of GLP-1s for reducing the progression of total knee arthroplasty.

Episode 10 addresses recent changes to the AACE diabetes guidelines and what pharmacists need to do to stay informed.

In part 2 of our interview with Sandra Leal, PharmD, MPH, she explored the ADA Standards of Care and how pharmacists are positioned to assist in interoperable diabetes management.

The executive order calls to realign core childhood vaccine recommendations with scientific evidence and best practices of peer, developed nations.

Pharmacists can prevent heat illness through medication reviews and safety plans.

Exploring both the PCV20 and PCV21 pneumococcal vaccines, researchers compare the differences in immune effects between patients at 50 and 65 years old.

Bepirovirsen suggests that a finite 24-week treatment course can achieve a functional cure defined as sustained undetectable hepatitis B surface antigen.

With insights from executives working around the clock to advance the pharmacy profession, our experts predicted what the landscape will look like following the Consolidated Appropriations Act of 2026.

Pharmacists flag risky medications, safeguard cold-chain supplies, and counsel with the HEAT checklist.

Pharmacist and diabetes expert Sandra Leal, PharmD, MPH, joins to discuss the importance of engaging pharmacists within primary care diabetes teams.

The approval arrives prior to the Prescription Drug User Fee Act action date of June 16, 2026.

In a meta-analysis conducted between 2013 and 2023, researchers explore the overall impact of interventions geared toward boosting pneumococcal vaccination rates.

Older adults with type 2 diabetes often juggle 5 or more different prescriptions.

Featuring pharmacist and entrepreneur Sam Maddula, PharmD, this episode explores some key legislative and regulatory insights regarding owning and operating a pharmacy business.

This regulatory milestone establishes inhaled insulin as the first and only noninjectable mealtime insulin option for children and adolescents.

Pharmacies can build clinical workflows, bill like providers, and get paid for MTM and test-and-treat services patients value.

Learn practical do’s and don’ts for male pharmacists to deliver private, inclusive, evidence-based birth control counseling patients trust.

Represented by Frier Levitt, multiple hospital systems filed lawsuits on May 21, 2026, targeting a variety of entities existing under CVS Health.

FDA updates Tremfya label in psoriatic arthritis, confirming it slows structural joint damage and helping patients protect mobility while easing symptoms.

In a health care landscape of silos and fragmentation, especially in the menopause space, pharmacists have increasingly provided their efforts to better care coordination for their communities.

Boost patient demand for pharmacist prescribing with clear messaging, service pages, in-store prompts, social posts, and local partnerships.

From supporting MTM services to reaching unhoused populations, the 340B program is a powerhouse for patient care, access, and affordability.

This month’s event will explore policy, people, and profitability, and how pharmacy businesses can transform these factors toward actionable solutions.

New FDA label lets linaclotide treat functional constipation in children 2 to 5, with dosing tips, mixing options, and key safety warnings.

Utah protocol streamlines large-volume immunoglobulin for measles-exposed infants as outbreaks surge.

In this episode, host Taylor Watterson, PharmD, PhD, provides a deeper look into workplace fatigue and the metrics used to calculate and facilitate it.

In part 2, Miller further breaks down the fragmentation of menopause care within today’s health care system and how pharmacists are uniquely positioned to fill in long-standing care gaps.

American College of Cardiology's new postpartum cardiovascular disease pathway urges early follow-up and tighter blood pressure goals.

Across rural US community pharmacies, researchers explore the common barriers and facilitators to pneumococcal vaccine uptake.

The FDA clears Hepcludex, the first chronic hepatitis D therapy, offering new hope with strong viral suppression data and key safety monitoring needs.

Two separate bills were marked up in House committees last week and were officially advanced to potentially move additional PBM reform into law.